Rare copy number variation in treatment-resistant major depressive disorder

Biological Psychiatry

Volumn 76, Issue 7, 2014, Pages 536-541

  O'Dushlaine, Colm ^a   Ripke, Stephan ^a   Ruderfer, Douglas M ^c   Hamilton, Steven P ^b   Fava, Maurizio ^a   Iosifescu, Dan V ^c   Kohane, Isaac S ^a   Churchill, Susanne E ^a   Castro, Victor M ^a   Clements, Caitlin C ^a   Blumenthal, Sarah R ^a   Murphy, Shawn N ^a   Smoller, Jordan W ^a   Perlis, Roy H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Copy number; Deletion; Duplication; Pharmacogenetic; Pharmacogenomic; Rare genetic variation

Indexed keywords

ANTIDEPRESSANT AGENT;

ACTIN FILAMENT; ARTICLE; CANCER SURVIVAL; CAUCASIAN; COPY NUMBER VARIATION; FEMALE; GENE; GENE DELETION; GENE DUPLICATION; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; MALE; MULTICENTER STUDY (TOPIC); PABPC4L GENE; PRIORITY JOURNAL; REMISSION; TREATMENT RESISTANT DEPRESSION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MAJOR DEPRESSION;

ACTIN CYTOSKELETON; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DNA COPY NUMBER VARIATIONS; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE;

EID: 84922683827     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2013.10.028     Document Type: Article

References (33)

1. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. (2006): Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR∗D report. Am J Psychiatry 163:1905-1917.
2. Gibson TB, Jing Y, Smith Carls G, Kim E, Bagalman JE, Burton WN, et al. (2010): Cost burden of treatment resistance in patients with depression. Am J Manag Care 16:370-377.
3. Perlis RH (2013): A clinical risk stratification tool for predicting treatment resistance in major depressive disorder. Biol Psychiatry 74:7-14.
4. Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD, et al. (2010): A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 67:133-138.
5. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, et al. (2009): A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 66:966-975.
6. GENDEP investigators, MARS investigators, STAR∗D investigators (2013): Common genetic variation and antidepressant efficacy in major depressive disorder: A meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry 170:207-217.
7. International Schizophrenia Consortium (2008): Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 455: 237-241.
8. Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, Steinberg S, et al. (2008): Large recurrent microdeletions associated with schizophrenia. Nature 455:232-236.
9. Elia J, Gai X, Xie HM, Perin JC, Geiger E, Glessner JT, et al. (2010): Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes. Mol Psychiatry 15:637-646.
10. Malhotra D, Sebat J (2012): CNVs: Harbingers of a rare variant revolution in psychiatric genetics. Cell 148:1223-1241.
11. Bergen SE, O'Dushlaine CT, Ripke S, Lee PH, Ruderfer DM, Akterin S, et al. (2012): Genome-wide association study in a Swedish population yields support for greater CNV and MHC involvement in schizophrenia compared with bipolar disorder. Mol Psychiatry 17:880-886.
12. Rucker JJ, Breen G, Pinto D, Pedroso I, Lewis CM, Cohen-Woods S, et al. (2013): Genome-wide association analysis of copy number variation in recurrent depressive disorder. Mol Psychiatry 18:183-189.
13. Degenhardt F, Priebe L, Herms S, Mattheisen M, Muhleisen TW, Meier S, et al. (2012): Association between copy number variants in 16p11.2 and major depressive disorder in a German case-control sample. Am J Med Genet B Neuropsychiatr Genet 159B:263-273.
14. Glessner JT, Wang K, Sleiman PM, Zhang H, Kim CE, Flory JH, et al. (2010): Duplication of the SLIT3 locus on 5q35.1 predisposes to major depressive disorder. PLoS One 5:e15463.
15. Rasmussen HB, Dahmcke CM (2012): Genome-wide identification of structural variants in genes encoding drug targets: Possible implications for individualized drug therapy. Pharmacogenet Genomics 22:471-483.
16. Perlis RH, Iosifescu DV, Castro VM, Murphy SN, Gainer VS, Minnier J, et al. (2011): Using electronic medical records to enable large-scale studies in psychiatry: Treatment resistant depression as a model. Psychol Med 42:41-50.
17. Gallagher PJ, Castro V, Fava M, Weilburg JB, Murphy SN, Gainer VS, et al. (2012): Antidepressant response in individuals with major depressive disorder exposed to NSAIDs: A pharmacovigilance study. Am J Psychiatry 169:1065-1072.
18. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, et al. (2004): Sequenced Treatment Alternatives to Relieve Depression (STAR∗D): Rationale and design. Control Clin Trials 25:119-142.
19. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. (2003): The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54:573-583.
20. Korn JM, Kuruvilla FG, McCarroll SA, Wysoker A, Nemesh J, Cawley S, et al. (2008): Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs. Nat Genet 40:1253-1260.
21. Zhang D, Qian Y, Akula N, Alliey-Rodriguez N, Tang J, Bipolar Genome Study, et al. (2011): Accuracy of CNV detection from GWAS data. PLoS One 6:e14511.
22. International Scizophrenia Consortium, Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, et al. (2009): Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460:748-752.
23. Raychaudhuri S, Korn JM, McCarroll SA, International Schizophrenia Consortium, Altshuler D, Sklar P, et al. (2010): Accurately assessing the risk of schizophrenia conferred by rare copy-number variation affecting genes with brain function. PLoS Genet 6:e1001097.
24. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. (2007): PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81:559-575.
25. Kim W, Bennett EJ, Huttlin EL, Guo A, Li J, Possemato A, et al. (2011): Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 44:325-340.
26. Cross-Disorder Group of the Psychiatric Genomics Consortium, Genetic Risk Outcome of Psychosis (GROUP) Consortium (2013): Identification of risk loci with shared effects on five major psychiatric disorders: A genome-wide analysis. Lancet 381:1371-1379.
27. Chang JC, Tomlinson ID, Warnement MR, Ustione A, Carneiro AM, Piston DW, et al. (2012): Single molecule analysis of serotonin transporter regulation using antagonist-conjugated quantum dots reveals restricted, p38 MAPK-dependent mobilization underlying uptake activation. J Neurosci 32:8919-8929.
28. Durand CM, Perroy J, Loll F, Perrais D, Fagni L, Bourgeron T, et al. (2012): SHANK3 mutations identified in autism lead to modification of dendritic spine morphology via an actin-dependent mechanism. Mol Psychiatry 17:71-84.
29. Piubelli C, Gruber S, El Khoury A, Mathe AA, Domenici E, Carboni L (2011): Nortriptyline influences protein pathways involved in carbohydrate metabolism and actin-related processes in a rat geneenvironment model of depression. Eur Neuropsychopharmacol 21: 545-562.
30. Gallagher PJ, Castro V, Fava M, Weilburg JB, Murphy SN, Gainer VS, et al. (2012): Antidepressant response in patients with major depression exposed to NSAIDs: A pharmacovigilance study. Am J Psychiatry 169:1065-1072.
31. Peters EJ, Slager SL, Kraft JB, Jenkins GD, Reinalda MS, McGrath PJ, Hamilton SP (2008): Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR∗D sample. PLoS One 3:e1872.
32. Wray NR, Pergadia ML, Blackwood DH, Penninx BW, Gordon SD, Nyholt DR, et al. (2012): Genome-wide association study of major depressive disorder: New results, meta-analysis, and lessons learned. Mol Psychiatry 17:36-48.
33. Psychiatric GWAS Consortium Bipolar Disorder Working Group (2011): Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet 43:977-983.